Literature DB >> 17278027

Leukoencephalopathy during administration of etanercept for refractory rheumatoid arthritis.

Motohisa Yamamoto1, Hiroki Takahashi, Hideki Wakasugi, Yasutaka Sukawa, Mayuko Saito, Chisako Suzuki, Yasuyoshi Naishiro, Hiroyuki Yamamoto, Yasuhisa Shinomura, Kohzoh Imai.   

Abstract

A 74-year-old Japanese woman was diagnosed with rheumatoid arthritis due to polyarthralgia. She was prescribed various disease-modifying anti-rheumatic drugs, but most of them were discontinued because of side effects or poor effectiveness. She was referred to our hospital in 2004, and etanercept was administered from June 2005. This resulted in rapid improvement of polyarthritis; however, she developed disorientation from February 2006. She was admitted to our hospital because of convulsions and loss of consciousness. She was diagnosed with progressive multifocal leukoencephalopathy on the basis of clinical symptoms and magnetic resonance imaging of the brain. In this significant and important case, leukoencephalopathy occurred during etanercept administration, and we refer to the risk of anti-TNFalpha drugs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17278027     DOI: 10.1007/s10165-006-0530-2

Source DB:  PubMed          Journal:  Mod Rheumatol        ISSN: 1439-7595            Impact factor:   3.023


  11 in total

1.  Neurological complications of biologic therapy in psoriasis: a review.

Authors:  Mark Bechtel; Catherine Sanders; Ann Bechtel
Journal:  J Clin Aesthet Dermatol       Date:  2009-11

Review 2.  [Infectious complications of biologic therapy in patients with rheumatoid arthritis].

Authors:  D Meyer-Olson; K Hoeper; R E Schmidt
Journal:  Z Rheumatol       Date:  2010-12       Impact factor: 1.372

3.  TNF-antagonist etanercept induced reversible posterior leukoencephalopathy syndrome.

Authors:  Oliver Kastrup; Hans Christoph Diener
Journal:  J Neurol       Date:  2008-02-20       Impact factor: 4.849

4.  Tocilizumab-associated multifocal cerebral thrombotic microangiopathy.

Authors:  Paul Jewell; Olaf Ansorge; Wilhelm Kuker; Sarosh R Irani; Giovanna Zamboni
Journal:  Neurol Clin Pract       Date:  2016-06

Review 5.  Tumor necrosis factor blockade and the risk of viral infection.

Authors:  Seo Young Kim; Daniel H Solomon
Journal:  Nat Rev Rheumatol       Date:  2010-02-09       Impact factor: 20.543

Review 6.  Rituximab therapy in lupus nephritis: current clinical evidence.

Authors:  Manuel Ramos-Casals; Candido Diaz-Lagares; Maria-Jose Soto-Cardenas; Pilar Brito-Zeron; María-José Cuadrado; Giovanni Sanna; Laura Bertolaccini; Munther A Khamashta
Journal:  Clin Rev Allergy Immunol       Date:  2011-06       Impact factor: 8.667

Review 7.  Update on PML: lessons from the HIV uninfected and new insights in pathogenesis and treatment.

Authors:  Elizabeth A Hartman; DeRen Huang
Journal:  Curr HIV/AIDS Rep       Date:  2008-08       Impact factor: 5.071

8.  Inflammatory infratentorial progressive multifocal leukoencephalopathy in a patient with rheumatoid arthritis.

Authors:  Boleslaw Lach; Barbara Connolly; Christian Wüthrich; Igor J Koralnik
Journal:  Neuropathology       Date:  2013-05-20       Impact factor: 1.906

Review 9.  Chimeric fusion proteins used for therapy: indications, mechanisms, and safety.

Authors:  Brian A Baldo
Journal:  Drug Saf       Date:  2015-05       Impact factor: 5.228

10.  An Overview of The Role of Tumor Necrosis Factor-Alpha in Epileptogenesis and Its Terapeutic Implications.

Authors:  Alexandre Michev; Alessandro Orsini; Viola Santi; Francesco Bassanese; Daniele Veraldi; Ilaria Brambilla; Gian Luigi Marseglia; Salvatore Savasta; Thomas Foiadelli
Journal:  Acta Biomed       Date:  2022-03-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.